These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 16834839

  • 1. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
    Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC.
    Curr Med Res Opin; 2006 Jul; 22(7):1403-13. PubMed ID: 16834839
    [Abstract] [Full Text] [Related]

  • 2. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Jul; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 3. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D, George MJ, Harrison LB.
    Cancer; 2003 Sep 01; 98(5):1072-9. PubMed ID: 12942577
    [Abstract] [Full Text] [Related]

  • 4. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug 01; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 01; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 6. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
    Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M.
    Nephrol Dial Transplant; 2005 Oct 01; 20(10):2146-52. PubMed ID: 15985516
    [Abstract] [Full Text] [Related]

  • 7. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 01; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 8. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 01; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 9. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Jun 01; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 10. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
    Glaspy JA, Charu V, Luo D, Moyo V, Kamin M, Wilhelm FE.
    Cancer; 2009 Mar 01; 115(5):1121-31. PubMed ID: 19170225
    [Abstract] [Full Text] [Related]

  • 11. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
    Granetto C, Ricci S, Martoni A, Pezzella G, Testore F, Mattioli R, Lampignano M, Tacconi F, Porrozzi S, Gasparini G, Mantovani G, EPO-ITA3 Study Group.
    Oncol Rep; 2003 Mar 01; 10(5):1289-96. PubMed ID: 12883695
    [Abstract] [Full Text] [Related]

  • 12. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb 01; 11(2):206-16. PubMed ID: 16476841
    [Abstract] [Full Text] [Related]

  • 13. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
    Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA.
    Cancer; 2006 Oct 15; 107(8):1909-17. PubMed ID: 16977654
    [Abstract] [Full Text] [Related]

  • 14. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb 15; 11(2):197-205. PubMed ID: 16476840
    [Abstract] [Full Text] [Related]

  • 15. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep 15; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 16. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.
    Lung Cancer; 2004 Oct 15; 46(1):119-24. PubMed ID: 15364140
    [Abstract] [Full Text] [Related]

  • 17. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS.
    Am J Gastroenterol; 2003 Nov 15; 98(11):2491-9. PubMed ID: 14638354
    [Abstract] [Full Text] [Related]

  • 18. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.
    J Am Med Dir Assoc; 2012 Mar 15; 13(3):244-8. PubMed ID: 21450214
    [Abstract] [Full Text] [Related]

  • 19. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.
    Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P.
    Clin J Am Soc Nephrol; 2010 Apr 15; 5(4):598-606. PubMed ID: 20185602
    [Abstract] [Full Text] [Related]

  • 20. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease.
    Benz R, Schmidt R, Kelly K, Wolfson M.
    Clin J Am Soc Nephrol; 2007 Mar 15; 2(2):215-21. PubMed ID: 17699416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.